Co-Targeting of the PI3K and RAS Pathways for the Treatment of Carcinoid Tumors

被引：0
|
作者：
Valentino, Joseph
Li, Jing
Kim, Ji Tae
Song, Jun
Mustain, W. C.
Weiss, Heidi L.
Anthony, Lowell
Townsend, Courtney M.
Evers, B. Mark
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [41] Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Saini, Kamal S.
    Loi, Sherene
    de Azambuja, Evandro
    Metzger-Filho, Otto
    Saini, Monika Lamba
    Ignatiadis, Michail
    Dancey, Janet E.
    Piccart-Gebhart, Martine J.
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 935 - 946
  • [42] In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways
    Daphu, Inderjit
    Horn, Sindre
    Stieber, Daniel
    Varughese, Jobin K.
    Spriet, Endy
    Dale, Hege Avsnes
    Skaftnesmo, Kai Ove
    Bjerkvig, Rolf
    Thorsen, Frits
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (05) : 8773 - 8794
  • [43] TARGETING THE PI3K/AKT/MTOR SIGNALING PATHWAYS IN CYSTIC FIBROSIS
    Reilly, R.
    Mroz, M.
    Dempsey, E.
    Shields, S.
    Wynne, K.
    McKone, E. F.
    Hiebel, C.
    Behl, C.
    Coppinger, J.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 200 - 200
  • [44] The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors
    Rogers, Hazel A.
    Estranero, Jasper
    Gudka, Keshni
    Grundy, Richard G.
    ONCOTARGET, 2017, 8 (02) : 2083 - 2095
  • [45] TARGETING THE RAS/MAPK AND PI3K/MTOR SIGNALING PATHWAYS: A NEW APPROACH IN SENSITIVE AND RESISTANT CML CELL LINES?
    Alves, R.
    Fonseca, R.
    Goncalves, A.
    Alves, V.
    Sarmento-Ribeiro, A.
    HAEMATOLOGICA, 2012, 97 : 212 - 212
  • [46] Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma
    May, Caitlin D.
    Landers, Sharon M.
    Bolshakov, Svetlana
    Ma, XiaoYan
    Ingram, Davis R.
    Kivlin, Christine M.
    Watson, Kelsey L.
    Al Sannaa, Ghadah A.
    Bhalla, Angela D.
    Wang, Wei-Lien
    Lazar, Alexander J.
    Torres, Keila E.
    CANCER BIOLOGY & THERAPY, 2017, 18 (10) : 816 - 826
  • [47] A natural inhibitor of c-Met that sensitizes head and neck cancer cells resistant to EGFR and PI3K co-targeting
    Anisuzzaman, Asm
    Hague, Abedul
    Butler, Brian
    Amin, Arm R.
    CANCER RESEARCH, 2019, 79 (13)
  • [48] Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
    Jaiswal, Bijay S.
    Janakiraman, Vasantharajan
    Kljavin, Noelyn M.
    Eastham-Anderson, Jeffrey
    Cupp, James E.
    Liang, Yuxin
    Davis, David P.
    Hoeflich, Klaus P.
    Seshagiri, Somasekar
    PLOS ONE, 2009, 4 (05):
  • [49] Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
    Sarker, Debashis
    Reid, Alison H. M.
    Yap, Timothy A.
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4799 - 4805
  • [50] Targeting PI3K/AKT/mTOR network for treatment of leukemia
    Bertacchini, Jessika
    Heidari, Nazanin
    Mediani, Laura
    Capitani, Silvano
    Shahjahani, Mohammad
    Ahmadzadeh, Ahmad
    Saki, Najmaldin
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2015, 72 (12) : 2337 - 2347
12345